Teva announces FDA approval of ProAir RespiClick (salbutamol sulphate) inhalation powder for paediatric asthma patients ages 4 to 11

29 April 2016 - Teva Pharmaceuticals announced today that the U.S. FDA has approved ProAir RespiClick (salbutamol sulphate) inhalation powder for the treatment or prevention of bronchospasm in children 4 to 11 years of age with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

The new paediatric indication provides a treatment option for children that eliminates the need for spacer and hand-breath co-ordination during inhalation.

ProAir RespiClick was approved by the FDA for use in patients 12 years of age and older in March 2015 and remains the only breath-activated, multi-dose, dry powder, short-acting beta-agonist inhaler available in the U.S.

For more details, go to: http://www.tevapharm.com/news/teva_announces_fda_approval_of_proair_respiclick_albuterol_sulfate_inhalation_powder_for_pediatric_asthma_patients_ages_4_to_11_04_16.aspx

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics , Asthma